Marfan’s syndrome

Published on 05/05/2015 by admin

Filed under Internal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 1 (1 votes)

This article have been viewed 1060 times

226 Marfan’s syndrome

Salient features

Examination

Proceed by examining:

Remember: Every patient should be referred for ophthalmic examination, annual echocardiography and genetic counselling to maximize the preventive potential in this disease.

Advanced-level questions

Is there a gene implicated in Marfan syndrome?

Marfan syndrome appears to be caused by mutations in a single gene FBN1 on chromosome 15 and encoding fibrillin (N Engl J Med 1992;326:905, Genomics 1993;17:468–75). Fibrillin is a glycoprotein produced by fibroblasts that aggregates alone or with other proteins in the extracellular matrix to form microfibrillary fibres on which elastin can be deposited. These fibres are particularly abundant in the ciliary zonules that support the lens, in ligaments and in the aorta. Dilatation of the aorta occurs as a result of cystic medionecrosis.

One study has suggested that the angiotensin II type 1 receptor antagonist losartan antagonizes the action of transforming growth factor-β in preventing aortic dilatation in mice with mutant fibrillin-1. Therapy for 6 months stopped progression of aortic dilatation and elastin fragmentation in the aortic wall, a histologic hallmark of Marfan syndrome. A beta-blocker, currently the therapy of choice for Marfan syndrome, was also effective but not as effective as losartan. In a small cohort study (n = 18), the use of an angiotensin II receptor antagonist in patients with Marfan syndrome significantly slowed the rate of progressive aortic root dilation (N Engl J Med 2008;358:2787). Another small study reported that perindopril reduced both aortic stiffness and aortic root diameter in patients with Marfan syndrome (JAMA 2007;298:1539–47). The US National Institutes of Health is sponsoring a clinical trial that will compare losartan with beta-blocker therapy in children and young adults with Marfan syndrome and aortic aneurysm.